Ceron α

“Remedy To Hepatic Tragedy”

Ceron α is a recombinant form of human interferon alpha 2b for injectable use mainly for the treatment of viral diseases including acute and chronic hepatitis B and C. Ceron α (Interferon Alfa 2b) is premier brand of Biocare Pharmaceutica is being prescribed by a vast majority of clinicians that includes but not limited to hepatologists and gastroenterologists. Ceron α has enjoyed the most prescribed interferon alfa 2b for the treatment of hepatitis. Selection of Ceron (Interferon Alpha) 2b 3MIU Injections, for five consecutive years in the “National Program for the Prevention and Control of Hepatitis” and “twice for Sindh Chief Minister’s Program for hepatitis” is witness to our quality assurance. We have supplied to the programs around 2.5 million and 2.3 million vials of Ceron Alpha 2b 3MIU injections respectively during the project duration. Total consumption of Ceron α was around 7400000 (7.4 million) back in 2008-09 per year not only that in fiscal year 2013/2014 Biocare Pharmaceutica supplied around 1162000 Ceron α (Interferon Alfa 2b) vials to chief minister’s program despite though competition from Peginterferon alfa 2a and 2b brands.


Ceron α (Interferon Alfa 2b) is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, and malignant melanoma.

Dosage Guidelines:

The usual recommend dosage for hepatitis C patients is 3 million international units IM or subcutaneously 3 times a week for 6-12 months depending upon genotype and 5 million international units once a day for 16 weeks for hepatitis b patients.


Ceron α (Interferon α 2b) is the injectable antiviral prescribed with oral antiviral Hepamed (Ribavirin), Ceron is available in two strengths having 3 MIU/Vial and 5 MIU/Vial. It come s with sterile water for reconstitution.


Ceron α (Interferon α 2b) must be kept at a temperature between 2-8 ˚C away from light.